Giandomenico Disabato

Dr. Giandomenico Disabato

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2025 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Closed access
AAAndrea Attanasio
Andrea Attanasio
GGGianluigi Guida
Gianluigi Guida
GDGiandomenico Disabato
Giandomenico Disabato
EGEmanuele Girani
Emanuele Girani
SBSara Boveri
Sara Boveri
MPMassimo Piepoli
Massimo Piepoli
Aims: Despite the advancements in the treatment of patients with heart failure with reduced ejection fraction (HFrEF), clinical inertia regarding the prescription of the four classes of guideline-directed medical therapies (GDMT) remains prevalent. This study aims to assess how adherence and time of prescription to GDMT in HFrEF impact mortality. Additionally, it seeks to evaluate sex differences in prescription and outcome. Methods and results: The study retrospectively analysed data worldwide using the TriNetX database. Patients with HFrEF were divided into four groups (G1–G4) based on the number of classes of GDMT prescribed. The primary endpoint was all-cause mortality. Additional analysis was performed in the G4 group to examine the impact of the time to reach quadruple therapy on mortality. An age-matched subgroup analysis was conducted to assess whether sex influenced mortality. The total cohort included 17 668 patients (68% men, mean age 66.7 ± 14.6). Only 20% of patients received quadruple therapy; the least heart failure (HF) medications prescribed were mineralocorticoid receptor antagonists (39%) and sodium-glucose cotransporter-2 inhibitors (33%), especially among older and frail patients. Each additional HF therapy was associated with significant mortality reduction (P-value < 0.001 for each additional class prescribed). However, the timing of full treatment implementation within the first year did not significantly affect mortality in the G4 group. No significant sex-based differences in survival were found in the age-matched analysis. Conclusion: Clinical inertia remains a critical issue, especially in those who may most benefit from HF therapy. Further clinical trials should specifically assess sex-related differences in drug efficacy and patient characteristics. Lay summary: Heart failure with reduced ejection fraction is a serious condition that affects many people worldwide. This study looked at how well heart failure medications are being used and their impact on survival. Out of all patients included, only a small percentage received all the recommended treatments, even though using more medications was linked to better survival. Differences between men and women were also noted, with women being older and having more health problems, but survival rates were similar when comparing men and women of the same age. These results highlight the need for better treatment approaches to improve outcomes for all patients.

15 December 2025 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Closed access
ACAntonia Camporeale
Antonia Camporeale
GGGianluigi Guida
Gianluigi Guida
MPMaurizio Pieroni
Maurizio Pieroni
FPFederico Pieruzzi
Federico Pieruzzi
PLPaola Lusardi
Paola Lusardi
MLMassimo Lombardi
Massimo Lombardi
Aims: Limited data exist about the prognostic significance of the processes underlying Fabry Disease (FD) cardiomyopathy (storage, hypertrophy, inflammation/fibrosis) as detected by cardiac magnetic resonance (CMR). Notably, T1 mapping has had limited prognostic application primarily due to poor reproducibility across different sequences and vendors. This CMR study aimed to identify the prognostic weight of the different mechanisms of FD cardiomyopathy and to develop a predictive score of adverse cardiovascular (CV) events. Methods and results: This prospective, observational study enrolled 167 FD patients, who underwent CMR at baseline. The study endpoint was the composite of all-cause death, heart failure hospitalization, new-onset atrial fibrillation/flutter, non-sustained/sustained ventricular tachycardia, major bradyarrhythmias, and myocardial infarction with non-obstructive coronary arteries. Over a median follow-up of 40 months, 27 patients (16%) experienced the primary endpoint. Left ventricle mass index (LVMI) [HR 1.02 (1.02–1.03), P < 0.001], presence of late gadolinium enhancement (LGE) [HR 20.12 (6.02–67.24), P < 0.001] and its extent [number of LGE + segments: HR 1.51 (1.33–1.71), P < 0001], and septal T1 [HR 0.98 (0.97–0.99), <0.001], measured in both ShMOLLI and MOLLI sequences, were associated with the composite endpoint. None of the patients with normal T1 experienced adverse CV events. A multivariable model including age, LVMI, number of LGE+ segments, and T1 value showed a good performance in predicting the composite endpoint. Conclusion: We propose a 3-year prognostic score to predict CV outcome in FD, including age, LVMI, number of LGE+ segments, and septal T1. Normal T1 has a negative predictive value for adverse CV events irrespective of the acquisition setting.

Verified
Journal Article
Open access
PDF file
Emanuele MicaglioEmanuele Micaglio
Emanuele Micaglio
LTLara Tondi
Lara Tondi
SBSara Benedetti
Sara Benedetti
MSMaria Alessandra Schiavo
Maria Alessandra Schiavo
ACAntonia Camporeale
Antonia Camporeale
MLMassimo Lombardi
Massimo Lombardi
PRKAG2 cardiomyopathy is a rare genetic disorder that manifests early in life with an autosomal dominant inheritance pattern. It harbors left ventricular hypertrophy (LVH), ventricular pre-excitation and progressively worsening conduction system defects. Its estimated prevalence among patients with LVH ranges from 0.23 to about 1%, but it is likely an underdiagnosed condition. We report the association of the PRKAG2 missense variant c.1006G>A p. (Val336Ile) with LVH, conduction abnormalities (short PR interval and incomplete right bundle branch bock) and early-onset arterial hypertension (AH) in a 44-year-old Caucasian patient. While cardiac magnetic resonance (CMR) showed a mild hypertrophic phenotype with maximal wall thickness of 17 mm in absence of tissue alterations, the electric phenotype was relevant including brady–tachy syndrome and recurrent syncope. The same variant has been detected in the patient’s sister and daughter, with LVH + early-onset AH and electrocardiographic (ECG) alterations + lipothymic episodes, respectively. Paying close attention to the coexistence of LVH and ECG alterations in the proband has been helpful in directing genetic tests to exclude primary cardiomyopathy. Hence, identifying the genetic basis in the patient allowed for familial screening as well as a proper follow-up and therapeutic management of the affected members. A review of the PRKAG2 cardiomyopathy literature is provided alongside the case report.

5 May 2025 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
AAAndrea Attanasio
Andrea Attanasio
JZJessica Zannoni
Jessica Zannoni
GDGiandomenico Disabato
Giandomenico Disabato
GGGianluigi Guida
Gianluigi Guida
LTLara Tondi
Lara Tondi
MLMassimo Lombardi
Massimo Lombardi
Aims: Anomalous Aortic Origin of Coronary Arteries (AAOCA) is associated with myocardial ischaemia and sudden cardiac death, particularly in young athletes. Although inducible myocardial ischaemia investigation is generally recommended, there is no clear indication of the most appropriate stress test, as the ECG exercise stress test presents low diagnostic accuracy. Dobutamine-stress cardiac magnetic resonance (dsCMR) has been proposed as a promising diagnostic tool, but its application has been limited to paediatric populations. This study aimed to evaluate the presence of inducible myocardial ischaemia assessed by dsCMR in AAOCA patients, regardless of age, and to identify factors associated with inducible myocardial ischaemia. Methods and results: In this single-centre observational study, 100 AAOCA patients who underwent dsCMR were enrolled from 2015 to 2024. dsCMR resulted positive in 14 cases, all showing perfusion abnormalities, with only one presenting segmental wall motion abnormalities. dsCMR was found to be safe without major adverse events. Factors significantly associated with inducible ischaemia included intramural course, the presence of ischaemic late gadolinium enhancement (LGE), and a history of acute coronary syndrome (ACS). Nine patients (9%) showed small areas of ischaemic LGE within the AAOCA territory, and they were older with a higher incidence of arterial hypertension, smoking habits and previous ACS episodes. Conclusion: dsCMR is a reliable test for the evaluation of myocardial ischaemia in AAOCA, especially for those with intramural course, ischaemic LGE, and previous ACS episodes. Although rare, older patients may have a myocardial ischaemic scar without alteration of ventricular function.

9 April 2024 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
PDF file
GDGiandomenico Disabato
Giandomenico Disabato
AAAndrea Attanasio
Andrea Attanasio
GGGianluigi Guida
Gianluigi Guida
MPMassimo Piepoli
Massimo Piepoli
This editorial refers to ‘Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study’, by A. Aimo et al., https://doi.org/10.1093/eurjpc/zwae093.

3 July 2026 in European Journal of Heart Failure
Verified
Journal Article
Closed access
ARAmina Rakisheva
Amina Rakisheva
GDGiandomenico Disabato
Giandomenico Disabato
AAAna Abreu
Ana Abreu
AAAndrea Attanasio
Andrea Attanasio
JBJohann G. Bauersachs
Johann G. Bauersachs
MPMassimo Piepoli
Massimo Piepoli
Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet sex-specific risk factors are usually not included in conventional predictive models. Specifically, heart failure (HF) in women may be influenced by sex-specific hormones and pathologies that need to be addressed to improve prevention and treatment. This expert consensus statement aims to provide a comprehensive roadmap for HF prevention and management across specific conditions affecting women during their life-course. Each section focuses on the impact of a specific female condition on CVD and how to prevent and manage HF in specific settings: 1. Pregnancy with a specific focus on how to deal with hypertensive disorders in the acute and chronic setting and how to prevent and treat Peripartum Cardiomyopathy (PPCM); 2. Gynecological conditions predisposing to HF, such as Polycystic Ovary Syndrome (PCOS), endometriosis, and the menopausal transition. Emphasis is placed on chronic inflammation, metabolic dysfunction, and the “window of opportunity” for Menopausal Hormone Therapy (MHT); 3. Cardio-Oncology: mitigating Cancer Therapy-Related Cardiac Dysfunction (CTRCD) in breast and gynecological cancers, focusing on female-specific cardiotoxicity profiles, the importance of subclinical detection of cardiac dysfunction and the implementation of cardioprotective strategies (ACE-inhibitors, Beta-blockers, SGLT2 inhibitors) during cardiotoxic treatments. Lifestyle interventions such as the DASH diet and exercise-based rehabilitation are highlighted as essential for maintaining cardiac reserve.